Man Group plc Takes $5.63 Million Position in Prestige Consumer Healthcare Inc. $PBH

Man Group plc bought a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 119,056 shares of the company’s stock, valued at approximately $5,628,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the period. Torren Management LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter worth about $35,000. Caitong International Asset Management Co. Ltd grew its stake in Prestige Consumer Healthcare by 69.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after purchasing an additional 236 shares in the last quarter. Finally, Danske Bank A S purchased a new position in shares of Prestige Consumer Healthcare during the third quarter valued at $37,000. 99.95% of the stock is currently owned by institutional investors.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Attractive value profile: A Zacks comparison of PBH and Stryker (SYK) highlights the value-investing case for Prestige Consumer Healthcare. PBH’s lower earnings multiple and defensive consumer-healthcare portfolio could support investor interest, although the comparison does not guarantee that PBH is the superior investment. PBH vs. SYK: Which Stock Is the Better Value Option?
• Positive Sentiment: Longer-term earnings growth: Zacks Research projects EPS of $4.55 for fiscal 2027, rising to $5.06 in fiscal 2028 and $5.25 in fiscal 2029. The forecasts imply improving earnings power and provide a potential catalyst if the company delivers.
• Neutral Sentiment: Quarterly estimates remain steady: Zacks forecasts EPS of $1.06 for fiscal Q2 2027, $1.22 for Q3 and $1.30 for Q4, followed by estimates of $1.14, $1.19, $1.38 and $1.35 for fiscal 2028’s quarters. These projections indicate expectations for consistent profitability rather than a near-term earnings surprise.
• Negative Sentiment: Analyst stance is cautious: Zacks Research maintains a “Hold” rating, and its fiscal 2027 EPS forecast of $4.55 is essentially in line with the $4.56 consensus estimate. That suggests the expected earnings growth is largely recognized in current expectations, limiting an immediate upgrade catalyst.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $52.48 on Friday. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 1.64 and a beta of 0.34. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $71.07. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The company’s 50-day moving average is $50.22 and its two-hundred day moving average is $54.62.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The business had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same period last year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on PBH. Canaccord Genuity Group decreased their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).